Education
About Us
Working with TipRanks
Follow Us
Idexx Laboratories (IDXX)
NASDAQ:IDXX
IDXX Stock Chart & Stats
$634.90
$7.33(1.72%)
At close: 4:00 PM EST
$634.90
$7.33(1.72%)
Day’s Range― - ―
52-Week Range$356.14 - $769.98
Previous CloseN/A
Volume277.29K
Average Volume (3M)506.10K
Market Cap
$50.00B
Enterprise Value$51.42B
Total Cash (Recent Filing)$180.07M
Total Debt (Recent Filing)$847.84M
Price to Earnings (P/E)48.6
Beta0.92
Next Earnings
May 06, 2026EPS Estimate
3.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.08
Shares Outstanding79,851,330
10 Day Avg. Volume612,043
30 Day Avg. Volume506,101
Financial Highlights & Ratios
PEG Ratio2.30
Price to Book (P/B)33.75
Price to Sales (P/S)12.59
P/FCF Ratio51.26
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue11.95
Enterprise Value/Gross Profit19.33
Enterprise Value/Ebitda35.00
Forecast
1Y Price Target
$778.57Price Target Upside22.63% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)14.52
Revenue Forecast (FY)$4.68B
Bulls Say, Bears Say
Bulls Say
Earnings And GuidanceAnalyst reiterates a Buy after the company beat revenue and profit expectations and issued guidance that supports continued organic revenue growth and margin expansion.
Product Innovation PipelineA robust innovation pipeline, including advanced cancer diagnostics and point-of-care platforms, is expanding testing capabilities and is expected to drive additional instrument placements and investor interest.
Recurring Consumables And Demographic TailwindAn expanding installed base of instruments plus stronger consumables placements, supported by higher utilization from an aging pet population, underpins recurring revenue growth.
Bears Say
Product Adoption SlowdownFollow-on placements of the inVue product are slowing relative to prior launches, suggesting more cautious customer adoption after an initial strong uptake.
Valuation And Margin PressurePremium valuation heightens sensitivity to any outlook revision, while tariffs and planned reinvestment may constrain operating margin expansion.
Veterinary Demand HeadwindsPressure on veterinary clinic visits and weakness in practice revenue create a demand headwind that could limit volume growth despite price increases.
Idexx Laboratories News
IDXX FAQ
What was Idexx Laboratories’s price range in the past 12 months?
Idexx Laboratories lowest stock price was $356.14 and its highest was $769.98 in the past 12 months.
What is Idexx Laboratories’s market cap?
Idexx Laboratories’s market cap is $50.00B.
When is Idexx Laboratories’s upcoming earnings report date?
Idexx Laboratories’s upcoming earnings report date is May 06, 2026 which is in 75 days.
How were Idexx Laboratories’s earnings last quarter?
Idexx Laboratories released its earnings results on Feb 02, 2026. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.933 by $0.147.
Is Idexx Laboratories overvalued?
According to Wall Street analysts Idexx Laboratories’s price is currently Undervalued.
Does Idexx Laboratories pay dividends?
Idexx Laboratories does not currently pay dividends.
What is Idexx Laboratories’s EPS estimate?
Idexx Laboratories’s EPS estimate is 3.43.
How many shares outstanding does Idexx Laboratories have?
Idexx Laboratories has 79,851,330 shares outstanding.
What happened to Idexx Laboratories’s price movement after its last earnings report?
Idexx Laboratories reported an EPS of $3.08 in its last earnings report, beating expectations of $2.933. Following the earnings report the stock price went down -4.603%.
Which hedge fund is a major shareholder of Idexx Laboratories?
Currently, no hedge funds are holding shares in IDXX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Idexx Laboratories Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$778.57 (22.63% Upside)
$778.57 (22.63% Upside)
Blogger Sentiment
Bullish
IDXX Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 153.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.88%
12-Months-Change
Fundamentals
Return on Equity
66.20%
Trailing 12-Months
Asset Growth
1.74%
Trailing 12-Months
Company Description
Idexx Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
IDXX Company Deck
IDXX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong operating performance with double-digit organic growth, record instrument placements, meaningful margin expansion, robust free cash flow and aggressive buybacks, and clear commercial and product momentum (InVue DX, CancerDx, Catalyst menu expansions, and software ARR growth). Headwinds include persistent weakness in same-store clinical visits (especially wellness), a decline in rapid assay revenues due to product transition, some instrument-revenue lapping and mix effects, and moderation in pricing. Overall, the positives (revenue/margin growth, cash generation, product commercialization and international strength) outweigh the cited challenges, and management provided constructive 2026 guidance that incorporates known headwinds.View all IDXX earnings summariesIDXX Revenue Breakdown
91.70% CAG
4.75% Water
3.13% LPD
0.42% Other
IDXX Stock 12 Month Forecast
Average Price Target
$778.57
▲(22.63% Upside)
Technical Analysis
Ownership Overview
0.28% Insiders
26.84% Mutual Funds
15.38% Other Institutional Investors
26.48% Public Companies and Individual Investors